Navigation Links
Echo Therapeutics Announces Appointments to Board of Directors
Date:2/15/2011

FRANKLIN, Mass., Feb. 15, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced the appointment of William F. Grieco and James F. Smith to its Board of Directors.  Echo's Board now has a majority of independent directors which is necessary to obtain a listing on a national exchange.

Mr. Grieco and Mr. Smith collectively bring to Echo Therapeutics over 60 years of extensive executive level industry, capital markets, regulatory and commercial experience with specific concentrations in healthcare and biotechnology.

"With the continued positive momentum that we have built at Echo and the anticipated near-term commercialization of our products setting the pace for an exciting future, we are pleased to have Bill and Jim join our Board of Directors," commented Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics.  "Bill and Jim have lifelong commercial industry experience and we look forward to benefiting from their substantial knowledge as the company moves from development to commercialization.  Importantly, both directors are independent which is necessary to obtain a national exchange listing."

Since 2008, Mr. Grieco has served as the Managing Director of Arcadia Strategies, LLC, a business and legal consulting organization servicing healthcare, science and technology companies.  He brings approximately 30 years of healthcare industry experience.  From 2003 to 2008 he served as Senior Vice President and General Counsel of American Science and Engineering, Inc., an x-ray inspection technology company, and prior to that he served as Senior Vice President and General Counsel of IDX Systems Corporation, a healthcare information technology company.  From 1995 to 1999, he was Senior Vice President and General Counsel for Fresenius Medical Care North America.  Mr. Grieco received a B.S. from Boston College, an M.S. in Health Policy and Management from Harvard University and a J.D. from Boston College Law School.  

Currently, Mr. Smith is Vice President and Chief Financial Officer of Orchid Cellmark, Inc., a leading international provider of DNA testing services, where he leads all aspects of finance, including control, financial reporting, tax, treasury, and M&A.  He brings over 30 years of financial management experience, including over 20 years, with Wyeth and American Cyanamid Company, most recently as Vice President of Finance.  During his time at Wyeth and Cyanamid, he obtained extensive commercial international business experience and was involved in numerous new product commercialization projects.  Mr. Smith started his accounting career at PricewaterhouseCoopers. He is licensed as a certified public accountant. 

About Echo TherapeuticsEcho Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.  Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking StatementsThe statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2009, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.For More Information:Patrick T. Mooney, M.D.

Media: Richard SternChairman and Chief Executive Officer

Stern & Co.(508) 530-0329

(212) 888-0044Connect With Us:- Visit our website at www.echotx.com  

- Follow us on Twitter at www.twitter.com/echotx

- Join us on Facebook at www.facebook.com/echotx

© 2002 – 2011  Echo Therapeutics, Inc. All rights reserved worldwide.


'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2017)... the nutrition division of Diplomat Specialty Infusion Group, is celebrating a decade ... To celebrate its anniversary, ThriveRx recently launched a redesigned website at ... improved organization to create the best user experience for consumers and health ... Diplomat ... "We,ve made several great strides throughout the past ...
(Date:7/1/2017)... 30, 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... conference call will be broadcast live over the Internet on ... news release detailing the quarterly results will be made available ... call. The live audio webcast can be accessed ... It will be archived for replay following the conference call. ...
(Date:6/27/2017)... 2017   NuEyes (NuEyes Technologies Inc.) today announced ... its growth in helping the legally blind live more independent ... the leading developer of augmented, virtual and mixed reality smartglasses ... The undisclosed funding amount was provided by strategic partners as ... offices in Abu Dhabi , ...
Breaking Medicine Technology:
(Date:7/18/2017)... Sherman Oaks, CA (PRWEB) , ... July 18, 2017 , ... ... and Ph.D. scientist extracted cannabis oils, announced today that at the WORLDZ Summit, taking ... Ryan will be speaking on the therapeutic benefits of medical cannabis for both pediatric ...
(Date:7/18/2017)... , ... July 18, 2017 , ... ... a lien basis, partners with the best medical professionals who offer the most ... pre-approves each medical professional in their network, ensuring that each patient receives prompt ...
(Date:7/18/2017)... Texas (PRWEB) , ... July 19, 2017 , ... ... Gold Winner for it’s Corporate Social Responsibility Initiative in the prestigious CEO World ... in leadership, innovation, organizational performance, new products and services, CEO case studies, corporate ...
(Date:7/17/2017)... ... 2017 , ... McGraw Family Pledges $3 Million for New Learning Center at ... Clinicians , NORWALK, Connecticut – July 17, 2017 – The McGraw family, founders ... health by pledging up to $3 million in a challenge gift to establish the ...
(Date:7/17/2017)... ... July 17, 2017 , ... ... Work For” by the Chronicle of Higher Education for the sixth consecutive year, ... which has campuses in Pomona, California and Lebanon, Oregon, was recognized in seven ...
Breaking Medicine News(10 mins):